Gladstone Institutes’ new project, supported by an initial $2 million grant from the National Institute of Allergy and Infectious Diseases—with the potential to increase funding up to $10 million over five years—aims to overcome these obstacles. This initiative, aptly named the Center for PhAIge Therapy, is designed to revolutionize phage therapy by integrating cutting-edge engineering techniques with advanced artificial intelligence (AI) models to develop precise, effective, and scalable treatments for antibiotic-resistant infections. By focusing on the notoriously difficult-to-treat ESKAPE pathogens, the Center is addressing some of the most pressing threats to contemporary medicine.

The ESKAPE pathogens—Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species—are notorious for their ability to evade conventional antibiotics and rapidly adapt to new drug regimens through genetic exchange of resistance elements. These opportunistic pathogens not only constitute a major source of hospital-acquired infections but also present a growing challenge due to their increasing resistance profiles. The World Health Organization has classified them as critical priority pathogens, urging urgent research for novel therapeutic approaches.

Gladstone’s Center for PhAIge Therapy, led by investigator Seth Shipman, PhD, is a cornerstone of a tri-institutional network funded through the Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP) program. This center’s scientific strategy involves combining high-throughput experimental platforms with sophisticated computational models to identify optimal phage-bacteria pairings. The goal is to move beyond the current empirical tactics to a predictive, rational design of phage therapies by generating large-scale datasets that elucidate the precise mechanisms of phage-bacterial interactions.

Fundamental to this approach is Gladstone’s recent technological breakthrough: precision genome editing tools that enable systematic engineering of phage genomes. By modifying specific genomic loci within phages, researchers can tailor phage infectivity and lytic activity to enhance therapeutic potential. The Center aims to leverage these tools along with AI algorithms to distill patterns of phage efficacy against various bacterial strains, ultimately facilitating the design of phage candidates with superior bactericidal capabilities against Klebsiella pneumoniae, a predominant and lethal ESKAPE pathogen responsible for a multitude of respiratory and bloodstream infections.

Complementing the genetic engineering work, the Center will also employ advanced phenotypic screening assays to dissect how individual phage components contribute to bacterial lysis and evasion of bacterial defense mechanisms. Such assays will provide critical insights into phage-host dynamics, informing both model refinement and phage optimization. This comprehensive experimental platform is designed to yield an unprecedented volume of data to feed machine learning algorithms, empowering models to predict phage effectiveness with clinical precision.

Moreover, the Center’s work extends into the realm of bacterium variability. Sukrit Silas, PhD, is characterizing the genetic and phenotypic diversity among Klebsiella pneumoniae strains to determine their differential susceptibility to various phage cocktails. By mapping this bacterial heterogeneity, the team aims to formulate phage combinations tailored to specific bacterial genotypes, thus maximizing therapeutic success rates and circumventing resistance development.

Integrated with these laboratory-based efforts is a computational analytics core led by Katie Pollard, PhD, who advances algorithms capable of evaluating compatibility between phage and bacterial strains, optimizing phage formulations for individualized treatments. The Center also benefits from Melanie Ott, MD, PhD, whose research involving human lung organoids offers a physiologically relevant context to study phage pharmacodynamics and therapeutic responses, bridging the gap between in vitro predictions and in vivo outcomes.

Together, this multidisciplinary team is constructing a synergistic feedback loop where iterative experiments inform AI model training, which in turn guides experimental design, accelerating progress in phage therapy development. This cycle enables the rapid identification and refinement of phage candidates, a paradigm shift from prior approaches that heavily relied on serendipity and small-scale case studies.

The broader CAPT-CEP initiative also includes complementary centers—such as the Center for Phage Pharmaceuticals at Stanford University, focusing on phage delivery mechanisms to the lung, and the University of Pittsburgh’s CAPT center, dedicated to developing assays for designing optimal dosing regimens. This collaborative network facilitates the sharing of assays, datasets, and expertise, fostering a unified effort to translate phage therapy into mainstream clinical practice.

Antibiotic-resistant infections are an escalating global health crisis, with an estimated 5 million deaths linked annually to resistant bacterial pathogens. Vulnerable populations, including immunocompromised cancer patients and hospitalized individuals reliant on invasive devices, are particularly affected. By harnessing the evolutionary specificity of phages and augmenting it with genome engineering and AI, the Center for PhAIge Therapy holds promise for delivering potent, tailored, and scalable therapeutic options against these formidable superbugs.

The project is supported by a five-year grant totaling up to $10,239,795 from the National Institute of Allergy and Infectious Diseases under the grant number P01AI195327, reflecting a significant federal investment in advancing bacteriophage therapeutics. Situated in San Francisco’s innovation hub, Gladstone Institutes exemplifies a research model that emphasizes visionary science, cross-disciplinary integration, and translational potential, positioning the Center for PhAIge Therapy at the forefront of combating antibiotic resistance.

Subject of Research: Development of AI-driven phage therapy to combat antibiotic-resistant ESKAPE pathogens
Article Title: Gladstone Institutes Launches AI-Driven Center to Revolutionize Phage Therapy Against Antibiotic-Resistant Superbugs
News Publication Date: Not specified
Web References:
– https://dom.pitt.edu/nih-funds-first-coordinated-u-s-research-network-for-phage-therapeutics/
– https://gladstone.org/people/seth-shipman
– https://gladstone.org/news/new-technology-could-lead-alternative-treatments-antibiotic-resistant-bacteria

Image Credits: Photo by Michael Short, Gladstone Institutes

Keywords: Bacteriophages, Viruses, Pathogens, Virology, Microorganisms, Artificial intelligence, Machine learning, Biotechnology, Antibiotic resistance, Drug resistance

Antibody-based therapies represent the vanguard of contemporary treatment modalities for malignancies and autoimmune conditions, leveraging the specificity and potency of immune molecules to target disease processes with unprecedented precision. However, the paradox of these therapies lies in their potential to provoke a spectrum of adverse reactions during first infusions, ranging from mild systemic symptoms such as shivering and fever to severe, life-threatening events including hypotension, respiratory distress, and extensive dermatological reactions. Dr. Elliott’s investigation aims to dissect the cellular and molecular underpinnings that govern these reactions, with a spotlight on the role of macrophages—versatile immune cells integral to innate immunity and inflammation.

The complexities of FIR are not merely clinical curiosities but represent a formidable hurdle in expanding the utility of immunotherapies. Despite the transformative potential of antibody treatments, patient experiences of FIR often necessitate hospitalization or discontinuation of therapy, underscoring an urgent need for mechanistic insights that could guide mitigation strategies. Dr. Elliott’s approach is grounded in examining how macrophages orchestrate the release of inflammatory cytokines—small signaling proteins that amplify immune responses and mediate inflammation during these critical episodes. By elucidating the signaling pathways that precipitate cytokine storms, his research could pave the way for targeted interventions to suppress or prevent FIR.

Elliott’s laboratory at the USA Health Mitchell Cancer Institute situates itself at the confluence of cancer immunotherapy and innate immune regulation. Drawing on advanced immunological techniques and state-of-the-art molecular biology tools, his work interrogates how macrophage activation dynamics and intercellular communication dictate the intensity and progression of inflammatory cascades during antibody infusions. This nuanced understanding holds the promise of identifying therapeutic checkpoints that modulate macrophage behavior without compromising the anti-tumor or immunomodulatory efficacy of the antibody agents.

The initial immune insults that trigger FIR can evolve rapidly, with patients experiencing chills, fever spikes, hypotension, dyspnea, and rashes that are indicative of systemic inflammatory activation. Such acute responses are believed to arise from complex interactions between infused therapeutic antibodies and the host’s immune system, eliciting macrophage activation and subsequent secretion of pro-inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β). These mediators potentiate vascular permeability, fever induction, and recruitment of additional immune effectors, forming a feedback loop that exacerbates tissue damage and clinical symptoms.

Despite extensive clinical documentation of FIR, the precise molecular and cellular events that precipitate severe toxicity remain inadequately characterized. Elliott’s initiative leverages cutting-edge experimental models that replicate the human immune milieu, enabling dissection of the signal transduction pathways and receptor interactions on macrophages responsible for cytokine induction. A key focus is the delineation of pattern recognition receptors (PRRs), Fc receptors (FcRs), and downstream signaling adaptors that might selectively trigger or amplify inflammatory responses upon exposure to therapeutic antibodies.

The translational potential of this research is profound. By demystifying the molecular language of FIR, Dr. Elliott’s team aspires to develop predictive biomarkers that can identify patients at heightened risk for severe reactions. Moreover, the identification of molecular targets for pharmacological intervention may enable clinicians to preemptively attenuate macrophage-driven inflammation through adjunct therapies or modified infusion protocols. Such interventions would not only enhance patient safety but could dramatically expand the eligible patient population for antibody-based treatments, revolutionizing standard care paradigms.

Elliott’s scientific journey, rooted in a Ph.D. from Wake Forest University School of Medicine, has consistently focused on innate immunity and macrophage biology, lending his expertise to the burgeoning field of cancer immunotherapy. His work at the USA Health Mitchell Cancer Institute—a premier cancer research and treatment hub on the Gulf Coast—integrates translational science with clinical imperatives. The institute’s commitment to advancing therapeutic frontiers ensures that this research will be closely linked to clinical trials and patient-centered outcomes.

Simultaneously, the Frederick P. Whiddon College of Medicine, where Elliott holds his academic appointment, embodies a progressive vision of medical education and research synergy. The college’s upcoming 250,000-square-foot facility is designed to foster interdisciplinary collaboration that accelerates biomedical discovery, positioning Elliott’s investigations within a vibrant ecosystem conducive to innovation. This vibrant academic environment, combined with institutional resources, augments the capacity to translate bench discoveries directly into transformative clinical interventions.

The implications of mastering FIR extend beyond cancer and autoimmune diseases, potentially informing a broader understanding of immune hyperactivation syndromes and cytokine-driven pathologies. The lessons gleaned from these studies could propel the design of next-generation immunotherapies with built-in safeguards against adverse reactions, optimizing the balance between therapeutic efficacy and patient safety. Elliott’s research epitomizes the intersection of sophisticated immunology with urgent clinical needs, embodying a translational ethos that promises to mitigate one of the most challenging obstacles to antibody therapy success.

As clinical immunotherapy increasingly becomes a mainstay in personalized medicine, the necessity to comprehend and conquer first infusion reactions cannot be overstated. Elliott’s investigation, grounded in rigorous scientific inquiry and supported by federal funding, paves the way for a future where antibody-based treatments are universally safer, more effective, and accessible to the diverse populations they are designed to serve. The outcomes of this project hold the potential to significantly enhance quality of life for patients struggling with cancers and autoimmune disorders, marking a milestone in the quest for precision immunotherapy.

In summary, Michael R. Elliott, Ph.D.’s research represents a critical effort to unravel the enigmatic mechanisms driving early infusion-related inflammatory reactions to antibody therapies. By focusing on the innate immune functions of macrophages and their cytokine signaling, this work aspires to facilitate safer immunotherapeutic applications. His contributions at the University of South Alabama, supported by robust funding and embedded within an innovative research community, underscore the dynamic progress at the forefront of immunology and oncology.

Subject of Research: Investigation of macrophage-mediated inflammatory mechanisms underlying first infusion reactions to antibody-based therapies in cancer and autoimmune disease patients.

Article Title: University of South Alabama Scientist Secures NIH Grant to Decode the Immune Triggers of First Infusion Reactions in Immunotherapy

News Publication Date: October 21, 2025

Web References: University of South Alabama Press Release

Image Credits: University of South Alabama

Keywords: antibody-based therapies, first infusion reactions, macrophage biology, inflammatory cytokines, immunotherapy, cancer treatment, autoimmune disease, innate immunity, cytokine signaling, NIH R21 grant, USA Health Mitchell Cancer Institute, Frederick P. Whiddon College of Medicine

Cryptosporidium protozoan parasites stand out as some of the most virulent waterborne pathogens globally, responsible for severe diarrheal diseases that disproportionately impact young children and immunocompromised adults. The two primary species, Cryptosporidium hominis and Cryptosporidium parvum, exert a deadly toll by causing intense diarrhea that leads to over 50,000 childhood deaths every year. Despite their profound health impact, these parasites linger in the shadows of global research efforts, lacking any approved curative therapies. Moreover, Cryptosporidium’s classification as a CDC Class B bioterrorism agent underscores its potential misuse as a weapon contaminating water supplies, heightening the urgency for dedicated research and medical countermeasures.

In response to this pressing crisis, Professor Cuny’s multi-institutional team brings together leading experts from the University of Houston, University of Washington, and Tufts University. Their collective mission is to harness the latest advancements in enzyme-targeting drug discovery to produce potent, selective inhibitors with the capacity to treat cryptosporidiosis effectively. This strategy pivots on targeting an essential parasite enzyme known as Calcium Dependent Protein Kinase 1 (CDPK1), whose inhibition has been shown to dramatically curtail parasite proliferation, marking it as a validated and highly promising drug target.

CDPK1 is a unique kinase enzyme critical for the survival and replication of Cryptosporidium parasites inside host intestinal cells. Silencing or chemically inhibiting CDPK1 disrupts key signaling pathways that the parasite depends on, resulting in arrested growth and eventual clearance. From a structural biology perspective, CDPK1 displays distinct active site features that differ from homologous human kinases, offering a valuable window for designing selective inhibitors that minimize off-target toxicity. This selectivity is paramount to developing safe therapeutics that spare human cells while dismantling the parasite’s life cycle.

The design philosophy employed by Cuny’s team incorporates not only molecular specificity but also advanced pharmacokinetic considerations to maximize efficacy. A novel aspect of their approach includes engineering drug candidates capable of enterohepatic recycling—a process by which the drug is absorbed through the liver, secreted into the bile, and then reabsorbed in the intestines, effectively prolonging its residence in the gastrointestinal tract. Such recycling enhances the local concentration of the compound where Cryptosporidium wreaks havoc—the intestines—thereby reducing systemic exposure and potential side effects.

This GI-targeting strategy represents a sophisticated leap forward in infectious disease pharmacology, as most antiparasitic drugs are limited by their rapid systemic elimination and insufficient concentrations at the site of infection. By tailoring drugs to persist in the intestinal lumen, Cuny’s team aims to achieve therapeutic concentrations capable of eradicating the parasite without posing undue systemic risk. Moreover, this targeted delivery concept not only holds promise for cryptosporidiosis but could revolutionize treatment paradigms for other gastrointestinal disorders, including inflammatory bowel diseases and certain colonic cancers, by concentrating active agents precisely where they are needed.

Beyond the drug design innovations, collaboration is a cornerstone of this expansive research effort. Ming Hu and Kevin Garey, both endowed professors at the University of Houston, bring expertise in drug discovery and development. Meanwhile, partners from the University of Washington, such as Wesley Van Voorhis, contribute infectious disease insights, and Saul Tzipori from Tufts University offers specialized knowledge in parasitology and pathogenesis. This convergence of multidisciplinary skills ensures that the drug candidates will not only be chemically robust but also biologically validated in relevant disease models.

The urgency of this research cannot be overstated; Cryptosporidium infections remain a leading cause of diarrheal mortality and morbidity in resource-limited and developed regions alike. The absence of effective treatments has perpetuated a cycle of suffering and death, especially among vulnerable populations such as children in low-income countries and people with compromised immune systems. As such, the development of targeted therapeutics represents a fundamental step toward addressing this neglected parasitic disease, with profound implications for global child health and biodefense.

By advancing CDPK1 inhibitors from the laboratory bench toward clinical candidates, the project endeavors to fill a critical void in parasitic disease treatment. Success in this realm would establish a new class of antiparasitic drugs with demonstrated efficacy and safety profiles, ultimately translating into lifesaving medicines that reach the populations in dire need. Furthermore, the scientific paradigm developed through this work will likely energize broader applications across infectious diseases and beyond, signifying a milestone in therapeutic innovation driven by mechanistic enzyme targeting.

Professor Cuny emphasizes that the long-term vision extends beyond individual drug discovery to an integrated approach encompassing pharmacology, toxicology, and clinical translation. The aspiration is to push CDPK1 inhibitors through advanced development stages expeditiously, culminating in treatments that are accessible, affordable, and adaptable to varied healthcare settings globally. This commitment to translational science epitomizes a new frontier in fighting parasitic diseases with precision medicine principles.

This initiative also underscores the significance of federal support from institutions like the National Institute of Allergy and Infectious Diseases, which recognize the critical need for investments in neglected tropical diseases. The nearly $4 million awarded to this effort not only fuels cutting-edge research but also signals a growing acknowledgment of the global health impact posed by parasites like Cryptosporidium. Such backing is essential to accelerating the path from scientific discovery to tangible public health outcomes.

The innovative targeting of CDPK1 as a validated drug target heralds a new era in combating cryptosporidiosis, a disease long overshadowed despite its deadly toll. With the fusion of molecular insight, drug design ingenuity, and collaborative expertise, this pioneering research at the University of Houston stands at the forefront of a transformative approach to tackling devastating parasitic infections that have eluded effective treatment for far too long.

Subject of Research:
Article Title:
News Publication Date:
Web References:
References:
Image Credits: University of Houston
Keywords: Parasitic diseases, Infectious diseases, Cryptosporidium, CDPK1, Drug targets, Drug development, Waterborne pathogens, Gastrointestinal infections, Pharmacology, Enzyme inhibitors, Bioterrorism agent

Currently, an estimated 40 million individuals worldwide live with HIV, a chronic condition that can be managed but not cured with existing treatments. The widely prescribed antiretroviral therapy (ART) efficiently suppresses HIV replication in the bloodstream but fails to address the virus’s ability to embed itself silently within certain immune cells. These infected cells harbor latent HIV reservoirs—viral DNA integrated into the genome of host cells, mostly CD4+ T lymphocytes—that evade immune detection and standard treatments. This viral dormancy poses one of the greatest challenges in HIV research, as these cells can reignite systemic infection if ART is interrupted.

The newly launched research program, known as Innovative Strategies for Personalized Immunotherapies and Reservoir Eradication (INSPIRE), will be helmed by Dr. Brad Jones, an associate professor specializing in microbiology and immunology within Weill Cornell Medicine’s Division of Infectious Diseases. Dr. Jones brings a rigorous scientific approach to dissecting the biology of HIV latency and is renowned for his pioneering work that previously secured a $28.5 million NIH grant targeting fundamental mechanisms governing the viral reservoir.

“This award confirms the crucial relevance of our research and underscores Weill Cornell Medicine’s emergence as a global epicenter for HIV cure research,” Dr. Jones stated. His team’s approach leverages advanced cellular and molecular techniques to untangle the complexities of the viral reservoir, aiming to eventually neutralize or eliminate these cells while restoring effective immune surveillance.

HIV’s lifecycle includes integration of its genetic material into host DNA, predominantly within CD4+ T cells. These cells can then transition into a latent state characterized by minimal to no viral protein expression, rendering the infected cells nearly invisible to the body’s immune defenses and unaffected by ART. Such latent cells are not only scarce but exhibit significant heterogeneity, evolving over time and differing markedly among patients. Understanding this diversity forms a core scientific challenge addressed by the INSPIRE program.

Central to this initiative is an exhaustive characterization of the HIV reservoir’s cellular landscape. The research team will use samples already collected from individuals living with HIV, employing state-of-the-art single-cell sequencing and phenotyping technologies. By delineating distinct reservoir subsets and identifying their molecular signatures and immune vulnerabilities, researchers aim to pinpoint precise targets for therapeutic intervention.

Building upon this refined knowledge, INSPIRE will explore cutting-edge therapeutic strategies inspired by advances in cancer immunotherapy. Unlike conventional approaches, the team intends to tailor treatments using a patient’s own immune effector cells, such as T cells and natural killer (NK) cells, engineered to recognize and eradicate virus-harboring cells. This personalized immunotherapy approach seeks to overcome the limitations posed by reservoir heterogeneity and variable immune responses.

Dr. Marina Caskey, a professor at The Rockefeller University and adjunct faculty at Weill Cornell Medicine, co-leads the INSPIRE program and emphasized the importance of individualized therapies in achieving durable HIV remission. “Because the reservoir and immune responses are unique to each individual, we believe tailored immunotherapies have the greatest potential to deliver sustained ART-free control or even permanent eradication of the virus,” she explained.

The researchers are also pioneering innovative approaches involving B cells—the antibody-producing arm of the immune system. Rather than relying solely on traditional vaccination, INSPIRE investigators plan to engineer and reinfuse autologous B cells that can continuously secrete broadly neutralizing antibodies (bNAbs) targeting diverse HIV strains. These bNAbs are capable of binding to multiple viral variants and neutralizing infectious particles, representing a potent weapon to suppress and potentially diminish the latent reservoir.

This approach addresses a critical challenge in HIV vaccine development, as conventional vaccines have struggled to elicit sufficiently potent and durable bNAb responses. By introducing B cells programmed to secrete these antibodies directly, the team hopes to establish a long-lived immunological barrier that controls viral rebound in the absence of ART.

Dr. Jones highlighted the significance of sustained bNAb presence, stating, “Maintaining broadly neutralizing antibodies in the bloodstream over long periods should effectively suppress the HIV reservoir and prevent viral resurgence without the need for continuous antiviral drugs. This might even reduce reservoir size over time, marking a critical step toward curative interventions.”

INSPIRE’s intricate research design combines immunology, virology, genomics, and bioengineering, reflecting the interdisciplinary nature necessary to tackle the complexities of HIV cure research. By integrating personalized immunotherapy with novel antibody strategies, the team aims not only to suppress but to fundamentally alter the landscape of HIV treatment, redefining what is possible for millions living with this virus.

The program benefits from collaborations that extend beyond Weill Cornell Medicine, involving key partners at The Rockefeller University, George Washington University, and components of the NIH itself. This collaborative network ensures a broad application of expertise and resources, maximizing the translational potential of the research toward clinical implementation.

As the field of HIV research pivots from lifelong viral suppression toward eradication and durable remission, initiatives like INSPIRE stand at the forefront of scientific innovation. Their success could usher in a new era of precision medicine for infectious diseases, where personalized immunotherapies close the chapter on HIV/AIDS as a global health threat.

Subject of Research: HIV Latency and Personalized Immunotherapy for HIV Cure

Article Title: Innovative INSPIRE Program Advances Personalized Immunotherapies to Eradicate Latent HIV Reservoirs

Web References:
https://vivo.weill.cornell.edu/display/cwid-rbjones
https://www.rockefeller.edu/our-scientists/research-affiliates/5615-marina-caskey/

Image Credits: Weill Cornell Medicine

Keywords: Human immunodeficiency virus, HIV research, Personalized medicine, Clinical medicine, HIV latency, Immunotherapy, Broadly neutralizing antibodies, Viral reservoirs, T cells, B cells, Natural killer cells, HIV cure strategies